Finding genetic variants in patients with heart failure undergoing breast cancer treatment
Exploratory Next Generation Sequencing to Identify Causative Variants for Therapy-Induced Congestive Heart Failure From Breast Cancer Study E5103 Germline DNA Samples
National Cancer Institute (NCI) · NCT02610426
This study is trying to find genetic changes in patients who have heart failure while being treated for breast cancer to help improve future treatments and understand their risks better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 162 (estimated) |
| Sex | All |
| Sponsor | National Cancer Institute (NCI) (nih) |
| Drugs / interventions | bevacizumab |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT02610426 on ClinicalTrials.gov |
What this trial studies
This research focuses on using whole exome sequencing to identify genetic variants in germline DNA samples from patients who have congestive heart failure while receiving treatment for breast cancer. The study aims to analyze previously collected DNA samples to uncover rare variants that may influence the risk of developing heart failure in these patients. By understanding the genetic changes associated with heart failure, the research could lead to better biomarkers and treatment strategies for affected individuals.
Who should consider this trial
Good fit: Ideal candidates include European American patients with available DNA who have developed congestive heart failure after breast cancer treatment, as well as African American patients with specific heart function criteria.
Not a fit: Patients who do not have a genetic predisposition to heart failure or who are not undergoing treatment for breast cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify genetic markers that predict heart failure risk in breast cancer patients, leading to improved patient management.
How similar studies have performed: Other studies utilizing whole exome sequencing have shown promise in identifying genetic factors related to various conditions, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * European American patients with DNA available * European American patients who developed CHF and patients who did not develop CHF following a full course of treatment with an anthracycline and bevacizumab * African American cases (based on a drop in left ventricular ejection fraction \[LVEF\] \< 50 or a drop from baseline \> 20 points) and African American controls
Where this trial is running
Boston, Massachusetts
- Eastern Cooperative Oncology Group — Boston, Massachusetts, United States (RECRUITING)
Study contacts
- Principal investigator: Bryan P Schneider — Eastern Cooperative Oncology Group
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Breast Carcinoma